1-2 of 2
Reece Marillier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Julie Preillon, Julia Cuende, Virginie Rabolli, Lucile Garnero, Marjorie Mercier, Noémie Wald, Angela Pappalardo, Sofie Denies, Diane Jamart, Anne-Catherine Michaux, Romain Pirson, Vincent Pitard, Martine Bagot, Shruthi Prasad, Erica Houthuys, Margreet Brouwer, Reece Marillier, Florence Lambolez, Joäo R. Marchante, Florence Nyawouame, Mathew J. Carter, Véronique Baron-Bodo, Anne Marie-Cardine, Mark Cragg, Julie Déchanet-Merville, Gregory Driessens, Catherine Hoofd
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (1): 121–131.
https://doi.org/10.1158/1535-7163.MCT-20-0464
Published: 05 January 2021
View article titled, Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
Open the PDF for Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies in another window
Includes: Supplementary data
Journal Articles

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Gregory Driessens, Derek Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin, Jie Guo, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Romain Pirson, Virginie Rabolli, Chad Ray, Nicole Streiner, Vince R. Torti, Konstantinos Tsaparikos, Benoit J. Van den Eynde, Martin Wythes, Li-Chin Yao, Xianxian Zheng, Joseph Tumang, Manfred Kraus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2530–2542.
https://doi.org/10.1158/1535-7163.MCT-17-1104
Published: 03 December 2018
View article titled, Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Open the PDF for Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy in another window
Includes: Supplementary data